Form 4: Director Brian Cherry Receives Atara Biotherapeutics Grant

Atara Biotherapeutics director Brian Cherry was granted 24,000 restricted stock units as part of his compensation package.

Summary

• Director Brian N. Cherry acquired 24,000 shares of common stock in the form of restricted stock units (RSUs).
• The transaction occurred on June 11, 2026.
• The shares were granted at a price of $0 per share as part of equity compensation.
• Following this transaction, the reporting person's total beneficial ownership is 62,320 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• The grant aligns the director's interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Vesting of the units is subject to the reporting person's continuous service to the company.

Future Outlook

The restricted stock units are scheduled to vest in three equal annual installments on the first, second, and third anniversaries of June 11, 2026, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure alignment between leadership and shareholders, particularly for companies in the clinical development stage.

Comparison to Industry Standards

• The use of multi-year vesting schedules for director equity is consistent with standard corporate governance practices in the U.S. biotech industry.
• The grant size is typical for non-employee director compensation packages at small-cap biopharmaceutical firms.

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity units.

Next Steps

• Vesting of 1/3 of the 24,000 shares on June 11, 2027.
• Vesting of 1/3 of the 24,000 shares on June 11, 2028.
• Vesting of 1/3 of the 24,000 shares on June 11, 2029.

Key Dates

Keywords

Atara Biotherapeutics, ATRA, Insider Trading, Form 4, Director Compensation, Equity Grant